Hong Kong Respiratory Medicine

Jean-Paul Sculier, Anne-Pascal Meert, Thierry Berghmans. The Lancet 2011; 377, Issue 9780: 1810 - 1812
In The Lancet , Roy Herbst and colleagues report the phase 3, double-blind, randomised BeTa trial, 1 in which they assessed the efficacy and safety of bevacizumab in combination with erlotinib, compared with erlotinib alone, for treatment of advanced non-small-cell lung cancer (NSCLC) after failure of first-line chemotherapy.

The study was designed to detect a 33% improvement in median survival. However, overall survival did not differ between treatment groups, with a median overall survival of 9·3 ...

Read more